Importantly, the consensus molecular subtypes (CMS) classified CRC subtypes into four groups based on genetic modifications and tumor immune profiling; CMS1 (MSI-H, immune activated), CMS2 (activated WNT and MYC signaling), CMS3 (dysregulation of metabolic pathways) and CMS4 (immune inflamed, TGF-β activation) [48]. The gene discussed is MYC; the disease is neoplasm.